Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax, lenalidomide and rituximab in patients with relapsed/refractory mantle cell lymphoma
2017-001060-38Phase 2Active
- Sponsor
- Nordic Lymphoma Group
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax, lenalidomide, rituximab in mantle cell lymphoma (MCL), sponsored by Nordic Lymphoma Group. Started Jan 2018; status: active.
02
Drugs
venetoclaxlenalidomiderituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2017-001060-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001060-38.